search

Active clinical trials for "Lymphoma, T-Cell"

Results 611-620 of 706

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma

This is a single arm, prospective trial to evaluate the efficacy and safety of Chidamide in combination with previous chemotherapy in peripheral T cell lymphoma patients who did not achieve complete response after 3 cycles of chemotherapy in interim evaluation.

Unknown status18 enrollment criteria

SIMPLE Chemotherapy for NK Lymphoma/Leukaemia

Non-Hodgkin's LymphomaRelapsed3 more

NK malignancies consist of two different clinical entities, extranodal NK/T cell lymphoma and aggressive NK leukaemia. Queen Mary Hospital (QMH) had started to use PIGLETS chemotherapy for treatment of NK malignancies since 2013, with promising results. The study in QMH had ended because of successful recruitment in the planned number of subjects. When PIGLETS was used in extranodal NK/T cell lymphoma, patients with stage I/II lymphoma have an overall response rate of nearly 90%, while patients with stage III/IV disease have an overall response rate of around 60%. The figures are comparable to the SMILE chemotherapy previously used. However, PIGLETS regimen carries much lower risk of nephrotoxicity when compared with SMILE. It has since become a standard protocol in management of NK malignancies in our institution. PIGLETS chemotherapy carries two major problems: the name PIGLETS may appear offensive to some religious populations. (e.g. Muslim) significant nausea/vomiting was seen in previous studies, and these could at least be partially alleviated with substance P antagonist aprepitant Thus the investigators decided to start a study, renaming the original PIGLETS regimen into SIMPLE chemotherapy, adding aprepitant as antiemetics and to recruit more patients for evaluation of clinical efficacy. The results of SIMPLE chemotherapy will be compared to SMILE in a non-inferiority trial setting.

Unknown status5 enrollment criteria

Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma

Cutaneous T-Cell Lymphoma (CTCL)

The purpose of this study is to evaluate the efficacy, safety and tolerability of SHAPE administered topically to skin lesions in patients with early-stage cutaneous T-cell lymphoma (CTCL).

Unknown status13 enrollment criteria

GDP in Frontline Chemotherapy for Patients With PTCL-NOS

LymphomaT-Cell1 more

This study is to evaluate the efficacy and safety of GDP (gemcitabine, dexamethasone, and cisplatin) chemotherapy in patients with peripheral T-cell lymphoma-NOS as frontline treatment.

Unknown status13 enrollment criteria

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With...

Peripheral T-Cell LymphomaNot Otherwise Specified5 more

Peripheral T-cell Lymphoma (PTCL) is a heterogenic malignancy with poor outcome. Five-year PFS and OS for these patients received classic CHOP regimen (cyclophosphamide, vincristin, doxorubicin and prednisone) is less than 30%.High dose intensive chemotherapy doesn't demonstrate better response. At present, there is no standardized treatment protocol for this kind of lymphoma. So, clinical trials are encouraged by NCCN for those patients.

Unknown status19 enrollment criteria

Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously...

Peripheral T-cell Lymphoma

This study is a Randomized Phase II Study to Compare Efficacy of CHOP versus Fractionated ICED in Transplant-eligible Patients with Previously Untreated Peripheral T-cell Lymphoma.

Unknown status39 enrollment criteria

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Peripheral T-cell Lymphoma NOSAnaplastic Large Cell Lymphoma4 more

This is a randomised, open-label phase II study comparing GEM-P chemotherapy (experimental arm) with CHOP (control arm) in previously untreated T-cell lymphoma. Eligible patients will be randomised 1:1 between 4-weekly GEM-P or 3-weekly CHOP chemotherapy.

Unknown status26 enrollment criteria

MESA Treatment for NK/T Cell Lymphoma

LymphomaExtranodal NK-T-Cell

Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma

Unknown status18 enrollment criteria

Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma

Extranodal NK/T-cell LymphomaNasal Type

The purpose of this study is to evaluate the efficacy and tolerability of radiotherapy followed by adjuvant chemotherapy in stage I/II NK/T-cell lymphoma.

Unknown status11 enrollment criteria

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Extranodal NK/T-cell LymphomaNasal Type

This is an open-label, multi-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 in subjects with relapsed or refractory extranodal NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.

Unknown status38 enrollment criteria
1...616263...71

Need Help? Contact our team!


We'll reach out to this number within 24 hrs